Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials

Keyphrases

• Psoriatic Arthritis 100%
• Risankizumab 100%
• Dactylitis 100%
• Enthesitis 100%
• Placebo 23%
• Patient-reported Outcomes 11%
• Complete Resolution 11%
• Leeds 11%
• Health-related Quality of Life 5%
• Interleukin-23 (IL-23) 5%
• Efficacy Outcomes 5%
• Alleviation 5%
• High Response Rate 5%
• Treatment Efficacy 5%
• Pathognomonic 5%
• Minimal Clinically Important Difference 5%
• Meaningful Improvement 5%
• Functional Assessment of Chronic Illness Therapy-fatigue 5%
• Resolution Rate 5%
• Index Assessment 5%
• Sustained Response 5%
• Pain-related Disability 5%
• Resolution Improvement 5%
• Musculoskeletal Lesions 5%
• Health Assessment Questionnaire Disability Index (HAQ-DI) 5%

Medicine and Dentistry

• Psoriatic Arthritis 100%
• Risankizumab 100%
• Dactylitis 100%
• Enthesitis 100%
• Placebo 23%
• Patient-Reported Outcome 11%
• Quality of Life 5%
• Combination Therapy 5%
• Chronic Disease 5%
• Interleukin 23 5%
• Post-Hoc Analysis 5%
• Pathognomonic 5%
• Minimal Clinically Important Difference 5%
• Functional Assessment 5%
• Health Assessment Questionnaire 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriatic Arthritis 100%
• Risankizumab 100%
• Enthesitis 100%
• Dactylitis 100%
• Placebo 23%
• Combination Therapy 5%
• Chronic Disease 5%
• Interleukin 23 5%